Renal Phase 3 Readout Calendar
Industry-sponsored renal trials with primary completion in the next 12 months or last 12 months.
Data last updated September 20, 2026 · source: ClinicalTrials.gov
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 renal trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Renal landscape →
Recently read out & awaiting topline — Renal
· 2Phase 3 renal trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Asset: Orforglipron | Type 2 Diabetes +5 | Completed | Q1 2026 2026-03-16 | Completed · awaiting
Updated 5mo ago
| NCT05803421 |
| Bayer | A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease Asset: Finerenone (BAY94-8862) | Non-diabetic Chronic Kidney Disease | Completed | Q4 2025 2025-12-31 | Completed · awaiting
Updated 7mo ago
| NCT05047263 |
Upcoming renal readouts — next 12 months
· 13Industry Phase 3 renal trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Kind Pharmaceuticals LLC | A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia Asset: AND017 capsules | Anemia Due to Chronic Kidney Disease | Recruiting | Q4 2026 2026-10-30 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07494409 |
| Ebima Clifford Okundaye | Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression Asset: QRX-3 | Chronic Kidney Diseases +2 | Not Yet Recruiting | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 12mo ago
| NCT06866236 |
| Humacyte, Inc. | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis Asset: Acellular Tissue Engineered Vessel (ATEV) | End Stage Renal Disease (ESRD) | Active Not Recruiting | Q4 2026 2026-10 (est.) | Estimated · stale
Updated 18mo ago
| NCT05908084 |
| Shaanxi Micot Pharmaceutical Techn… | Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism Asset: MT1013 | Secondary Hyperparathyroidism, Chronic Kidney Disease | Recruiting | Q4 2026 2026-11-26 (est.) | Estimated · aging
Updated 12mo ago
| NCT07122401 |
| Kind Pharmaceuticals LLC | A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Asset: AND017 | Anemia Due to Chronic Kidney Disease | Recruiting | Q4 2026 2026-12-01 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07487727 |
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.